PET imaging in neuroendocrine tumors: Current status and future prospects

Minerva Endocrinologica

Volumn 33, Issue 3, 2008, Pages 257-275

  Basu, S ^a,b   Kumar, R ^a,c   Rubello, D ^d   Fanti, S ^e   Alavi, A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Neuroendocrine tumors; Positron emission tomography; Receptors, somatostatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68; 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID DEXTRO 1 PHENYLALANINE 3 THYROSINE 8 THREONINE OCTREOTIDE; 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID CU 64; 3,4 DIHYDROXYPHENYLALANINE GA 68; 5 HYDROXYINDOLEACETIC ACID; 6 FLUORODIHYDROXYPHENYLALANINE F 18; 6 FLUORODOPA F 18; ACETYL HYPOFLUORITE F 18; CHROMOGRANIN A; COPPER 64; CYCLAM; DIETHYLENETRIAMINE PENTAACETIC ACID DEXTRO 1 PHENYLALANINE PENTETREOTIDE IN 111; EPHEDRINE C 11; FLUORODEOXYGLUCOSE F 18; GADOTERIC ACID; IODINE 123; IODINE 131; MINIGASTRIN GA 68; NEURON SPECIFIC ENOLASE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; COPPER; DIAGNOSTIC AGENT; GALLIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; TUMOR MARKER; TUMOR PROTEIN;

ABDOMEN; CARCINOID; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; EAR CANCER; ECHOGRAPHY; GASTROINTESTINAL TRACT; HUMAN; HYPERINSULINISM; INSULINOMA; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS ISLET CELL TUMOR; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION; CHEMISTRY; FORECASTING; MEDULLARY CARCINOMA; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; COPPER RADIOISOTOPES; FORECASTING; GALLIUM RADIOISOTOPES; HUMANS; HYPERINSULINISM; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 53049085340     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Arnold R, Göke R, Wied M, Behr T. Neuroendocrine Gastro-Entero-Pancreatic (GEP) Tumors. In: Scheppach W, Bresalier RS, Tytgat GNJ, editors. Gastrointestinal and liver tumors. Heidelberg: Springer; 2004. p. 195-233.
2. Ramage JK, Davies AHG, Ardill J, Bax N, Caplin M, Grossman A et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54(2005):iv1-iv16.
3. Warner RRP. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005;128:1668-84.
4. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991;36:933-42.
5. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
6. Öberg K. Carcinoid tumors: current concepts in diagnosis and treatment. The Oncologist 1998;3:339-45. (Pubitemid 28485575)
7. García-Yuste M, Matilla JM, González-Aragoneses F. Neuroendocrine tumors of the lung.Curr Opin Oncol 2008;20:148-54.
8. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch 2007;451(Suppl 1):S51-9.
9. Krulich L, Fawcett CP. The hypothalamic hypophysiotropic hormones. Int Rev Physiol 1977;16:35-92.
10. Krulich L, Quijada M, Wheaton JE, Illner P, McCann SM. Localization of hypophysiotropic neurohormones by assay of sections from various brain areas. Fed Proc 1977;36:1953-9.
11. Lucey MR. Endogenous somatostatin and the gut. Gut 1986;27:457-67.
12. Newman JB, Lluis F, Townsend CMJ. Somatostatin. New York, NY: McGraw-Hill Book Co.; 1987.
13. Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med1987;109:320-6.
14. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Atomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005;52:605-11.
15. Rufini V, Calcagni MLC, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
16. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997;70:471-9. (Pubitemid 28515732)
17. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin tracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
18. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumour uptake. J Nucl Med 1999;40:762-7.
19. Green MS, Welch MJ. Gallium radiopharmaceutical chemistry. Int J Rad Appl Instrum B 1989;16:435-48.
20. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93.
21. Hofmann M, Maecke H, Borner A, Weckesser E, Schoffski P, Oei L et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTA-TOC: preliminary data. Eur J Nucl Med 2001;28:1751-7.
22. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3- Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42-8.
23. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-22.
24. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18.
25. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007;28:359-63.
26. Kahn S, Win Z, Szyszko T, Lloyd C, Dunn J, Alavi A, Al-Nahhas A. PET Imaging of pheochromocytoma. PET Clinics of North America (In Press).
27. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053-6. (Pubitemid 32595304)
28. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS et al. The efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol 1997;24:35-43.
29. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21.
30. 18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum [A] 1990;41:275-81.
31. Luxen A, Guillame M, Melega WP, Pike VW, Solin O, Wagner R. Production of 6-[18F]fluoro-L-DOPA and its metabolism in viva a critical review. Nucl Med Biol 1992;19:149-58.
32. 18F]-fluoro-L-DOPA. Appl Radiat Isot 1999;51:389-94.
33. 18F]fluoro-D-DOPA. J Labelled Comp Radiopharm 2007;50:1236-41.
34. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY.6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008;49:573-86.
35. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333-7.
36. 18F-fluorodopa PET scan. J Pediatr 2007;150:140-5.
37. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80. (Pubitemid 32667172)
38. 18F-DOPA whole body PET-initial results. Radiology 2002;222:507-12.
39. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-94.
40. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47:1455-62.
41. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C et al. Brain tumor imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-7.
42. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904-11.
43. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9.
44. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47.
45. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nud Med Mol Imaging 2005;32:724.
46. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V et al. Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;3 [Epub ahead of print].
47. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D et al. Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 17 [Epub ahead of print].
48. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21. (Pubitemid 32150511)
49. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008;49:524-31.
50. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-94. (Pubitemid 36612951)
51. 18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1604-9.
52. Suchi M, MacMullen C, Thornton PS, Ganguly A, Stanley CA, Ruchelli ED. Histopathologyof congenital hyperinsulinism: retrospectivestudy with genotype correlations. Pediatr Dev Pathol 2003;6:322-33.
53. Rahier J, Sempoux C, Fournet JC, Poggi F, Brunelle F, Nihoul-Fekete C, Saudubray JM, Jaubert F. Partial or near-total pancreatectomy for persistent neonatal hyperinsulinaemic hypoglycaemia: the pathologist's role. Histopathology 1998;32:15-9.
54. Sempoux C, Guiot Y, Lefevre A, Nihoul-Fékété C, Jaubert F, Saudubray JM et al. Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome and keys for differential diagnosis. J Clin EndocrinolMetab 1998;83:1455-61.
55. Verkarre V, Fournet JC, de Lonlay P, Gross-Morans MS, Devillers M, Rahier J et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286-91.
56. de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999;340:1169-75.
57. Dubois J, Brunelle F, Touati G, Sebag G, Nuttin C, Thach T et al. Hyperinsulinism in children:diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Pediatr Radiol 1995;25:512-6.
58. Fékété CN, de Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray JM et al. The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg 2004;39:267-9.
59. Ferry RJ Jr, Kelly A, Grimberg A, Koo-McCoy S, Shapiro MJ, Fellows KE et al. Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. J Pediatr 2000;137:239-46.
60. Stanley CA, Thornton PS, Ganguly A, MacMullen C, Underwood P, Bhatia P et al. Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinismby intravenous acute insulinresponse tests and selective pancreatic arterial calciumstimulation. J Clin Endocrinol Metab 2004;89:288-96.
61. Grimberg A, Ferry RJ Jr, Kelly A, Koo-McCoy S, Polonsky K, Glaser B et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes 2001;50:322-8. (Pubitemid 32127289)
62. 18F-fluoro-L-DOPA. J Nucl Med 2005;46:560-6. (Pubitemid 41716398)
63. 18F]fluoro-L- dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab 2006;91:933-40.
64. 18F]-DOPA positron emission tomography. Diabetes 2006;55:13-8.
65. 18F]-dopa positron emission tomography. J Clin Endocrinol Metab 2006;91:2839-42.
66. 18F-DOPA- PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006;66:40-2.
67. Pampaloni-Hernandez M, Zhuang H, Fanti S, Alavi A. Emission Tomography Imaging and hyperinsulinism. PET Clinic North America (In Press).
68. Hardy OT, Hernandez-Pampaloni M, Saffer JR. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 2007;92:4706-11.
69. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007;92:1237-44.
70. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 2003;30:1266-9.
71. 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248-56. (Pubitemid 32150515)
72. 111In) SPECT data. Mol Imaging Biol 2005;7:257-61.
73. 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism: a pilot study. Nuklearmedizin 2006;45:193-6. (Pubitemid 44645965)
74. 18F DOPA whole body PET - initial results. Radiology 2002;222:507-12.
75. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-94. (Pubitemid 36612951)
76. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-34.
77. Urhan M, Alavi A, Nanni C. The evolving role of Positron Emission Tomography Imaging in medullary thyroid carcinoma. PET Clinics of North America (In Press)..
78. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47:1455-62.
79. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 2008;34:581-6.
80. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008;61:54-60.